Quick answers
- What is Octreotide used for?
- The FDA-approved label (Mycapssa, Chiesi USA, Inc., July 24, 2025) says: “MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide ( 1 ).” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Octreotide have a boxed warning?
- No. None of the 2 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Octreotide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Octreotide been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Octreotide?
- 2 companies list prescription products of Octreotide in the FDA NDC Directory, including Amryt Pharmaceuticals Designated Activity Company and Chiesi USA, Inc..
What Octreotide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide ( 1 ).
— FDA label: Mycapssa, Chiesi USA, Inc., effective July 24, 2025. Read the full label on DailyMed →
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 2 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Capsule, delayed release |
|---|---|
| Route | Oral |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Mycapssa |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Amryt Pharmaceuticals Designated Activity Company1 product
- Chiesi USA, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA208232 MYCAPSSA | Chiesi | June 26, 2020 | 1, latest July 11, 2024 2024: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2380611, 2380617 |
|---|---|
| SPL set ID of the quoted label | 58d80bc6-bdfb-4908-93e7-aace447c8d1a |
| FDA labels (SPL) | 2 |
| FDA applications | NDA208232 |
| Active ingredients (FDA) | OCTREOTIDE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Mycapssa, Chiesi USA, Inc., effective July 24, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →